Sign in Subscribe

Building a Research Business: Navigating Payment Challenges with Control and Stability

A merchant building a peptide research website recently highlighted the significant hurdles involved — particularly around compliance, disclaimers, lab result integration, and finding reliable payment solutions for research compounds. At Blockonomics, we have worked with businesses in regulated and high-risk categories for over a decade. We understand the unique pressures these operations face.

This article reflects on those challenges and explains how we have designed our infrastructure to support merchants who need dependable, low-risk payment options.

The Complexities of Operating a Peptide Research Business

Peptide research products operate in a regulated environment. Merchants must maintain strict compliance with disclaimers (typically "Research Use Only"), provide proper Certificates of Analysis (COAs) and lab documentation, and structure websites with clear medical-style professionalism.

Despite operating legally for research purposes, many peptide businesses encounter repeated difficulties with traditional payment processors. Mainstream providers often classify research chemicals and peptides as high-risk or restricted, leading to:

  • Sudden account reviews, freezes, or terminations.
  • Elevated chargeback rates due to product expectations, shipping timing, or unrecognized charges.
  • Higher fees and rolling reserves from specialized high-risk processors.
  • Limited flexibility for global customers.

These issues create operational uncertainty and can threaten business continuity, even for compliant operations.¹ This is an understandable concern for anyone scaling a peptide research site — finding payment infrastructure that supports compliance without adding unnecessary risk or cost is critical. Many peptide businesses specifically face heightened compliance requirements and stricter chargeback thresholds.² The regulatory environment is closely monitored by the FDA, which has issued warning letters to companies selling peptides for unapproved uses.³ A common difficulty is sudden account freezes and terminations by payment processors, with funds sometimes held for up to 180 days.⁴

Our Established Approach at Blockonomics

Since 2015, Blockonomics has followed a focused and considered path: building non-custodial cryptocurrency payment solutions that emphasize merchant ownership and transaction finality.⁵ In 2025, the platform processed over 350,000 transactions and maintained a direct-to-wallet architecture that ensures merchants receive 100% of their funds directly, with zero counterparty risk.⁶ Non-custodial architecture has been documented to reduce the risk of fund freezes and other external restrictions.⁷ We do not position ourselves as a full replacement for every payment method but as a stable, complementary option for businesses seeking to reduce dependency on high-risk traditional rails.

How Blockonomics Supports Peptide Research Merchants

Our infrastructure is designed to address the specific needs of research chemical and peptide businesses:

1. Non-Custodial Payments – Direct to Your Wallet
Every payment settles straight into the wallet you control. This removes third-party holds, reduces settlement delays, and minimizes counterparty risk — critical in categories where processors may freeze funds during reviews. By design, Blockonomics does not hold funds for "security" or "compliance" purposes.⁸

2. Significantly Lower Chargeback and Dispute Risk
Blockchain transactions are irreversible once confirmed. This eliminates most friendly fraud and chargeback mechanisms common in peptide sales, where disputes often arise from expectation gaps or shipping issues. Shifting even part of your volume to crypto can meaningfully protect margins. Global chargebacks cost eCommerce an estimated $33.79 billion in 2025, a figure projected to rise to $41.69 billion by 2028.⁹ Friendly fraud accounts for roughly 61% of all chargebacks (where a legitimate customer disputes a valid charge), making irreversible settlement particularly valuable.¹⁰

3. Multi-Coin Support – Practical Flexibility
We support multiple cryptocurrencies to meet diverse customer needs:

  • Bitcoin (BTC): The most established cryptocurrency, with ~58–60% market dominance. It carries strong recognition and trust, appealing to customers who value security and long-term stability. In 2025, Bitcoin's market dominance remained above 50% all year, reaching 58.8% as of December.¹¹
  • Bitcoin Cash (BCH): Offers faster confirmations and lower fees, making it suitable for research product purchases.¹²
  • USDT (Tether): A leading stablecoin that provides price certainty. Stablecoins processed over $33 trillion in transaction volume in 2025 (a 72% increase from the prior year), helping reduce volatility-related concerns and buyer hesitation in research purchases.¹³

This multi-coin approach gives customers choice while keeping operations simple for the merchant.

4. Transparent and Low Fees
We apply a clear 1% fee per transaction after the first 10 free each month, with no hidden markups or long-term contracts.¹⁴ This predictability is especially valuable when managing compliance-related costs.

5. Clean Integrations and Setup
Blockonomics offers straightforward API support and integrations suitable for custom or WooCommerce-based websites.¹⁵ This allows compliant product pages, disclaimers, and lab integrations to work seamlessly with payment flows.

6. Privacy and Compliance Alignment
Our design minimizes unnecessary data collection, supporting the privacy-focused approach many research businesses prefer while maintaining necessary operational records. Blockonomics is a no-KYC, non-custodial platform, and because it never holds funds, it is not a money transmitter in the traditional sense.¹⁶

The Considered Benefits for Peptide Research Businesses

Incorporating Blockonomics alongside other methods can deliver:

  • Greater Payment Stability: Reduced exposure to sudden processor shutdowns common in the peptide space.
  • Improved Cash Flow: Immediate wallet settlement and final transactions mean faster, more reliable access to funds.
  • Broader Customer Reach: Attract research-oriented customers comfortable with crypto, many of whom prefer privacy and have higher purchasing power.
  • Risk Diversification: Less reliance on traditional high-risk merchant accounts that often come with reserves and scrutiny.

We recognize that many peptide businesses still process a portion of their volume through cards. Our solution serves as a practical, established complement for those prioritizing long-term reliability.

Exploring Solutions for Your Needs

If you are developing a compliant peptide research website and evaluating payment options, we encourage you to assess solutions based on your compliance requirements, target customers, and risk profile.

For those interested in Blockonomics, our documentation, testing sandbox, and setup guides are available on our website. We focus on providing clear resources to support informed implementation.

Final Thoughts

Operating in the peptide research space requires careful attention to compliance, website structure, and payment infrastructure. Merchants deserve solutions that align with regulatory realities while offering control and stability.

At Blockonomics, we remain focused on delivering dependable, non-custodial multi-coin payments built for these challenges. We have maintained this approach for over ten years because we believe merchant-owned, final transactions represent a more sustainable foundation for specialized businesses.

We welcome thoughtful discussions with operators navigating these complexities and are committed to contributing constructively to the payments landscape.

Blockonomics – Established Bitcoin & Multi-Coin Payment Infrastructure Since 2015

References

  1. Merchant Risk Council. (2024). High-Risk Vertical Report: Nutraceuticals and Research Chemicals.
  2. FDA. (2023). Guidance for Industry: Compounded Drug Products Under Section 503A.
  3. U.S. Food and Drug Administration. (2024). Warning Letters: Unapproved Peptide Products. Retrieved from https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
  4. Electronic Transactions Association. (2025). Merchant Account Underwriting and Reserve Practices.
  5. Blockonomics. (2025). Non-Custodial Payment Architecture Whitepaper. Retrieved from https://www.blockonomics.co/whitepaper
  6. Blockonomics Internal Data (2025). Platform Transaction Volume Report.
  7. CoinDesk Research. (2024). The Case for Non-Custodial Payments in High-Risk Industries.
  8. Blockonomics Support Documentation. (2025). How Non-Custodial Payments Work. Retrieved from https://www.blockonomics.co/support
  9. Nilson Report. (January 2026). Global Chargeback Statistics 2025, Issue 1245.
  10. Chargebacks911. (2025). Friendly Fraud: 2025 Annual Report.
  11. CoinMarketCap. (December 2025). Bitcoin Dominance Historical Data. Retrieved from https://coinmarketcap.com/charts/bitcoin-dominance/
  12. Bitcoin Cash Project. (2025). Transaction Speed and Fee Comparison. Retrieved from https://bitcoincash.org/
  13. The Block Research. (January 2026). Stablecoin Transaction Volume 2025 Year-End Report.
  14. Blockonomics Pricing Page. (2025). Transparent Fee Structure. Retrieved from https://www.blockonomics.co/pricing
  15. Blockonomics Developer Docs. (2025). WooCommerce and API Integration Guides. Retrieved from https://www.blockonomics.co/developers
  16. Blockonomics Privacy Policy. (2025). No-KYC and Non-Custodial Statement. Retrieved from https://www.blockonomics.co/privacy

Comments ()